Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies
Certolizumab Pegol Prescribing Information. Available at www.accessdata.fda.gov/scripts/cder/daf/index.cfm;
Certolizumab Pegol Summary of Product Characteristics. Available at www.ema.europa.eu/ema;
Blauvelt A et al. JEADV 2019;33(suppl 3):21–2;
Gisondi P et al. Int J Mol Sci 2017;18:2427.
Abstract - 85 Poster PDF - 35
- There are currently no refbacks.